Pfizer (PFE) Revenue (2009 - 2026)

Pfizer has disclosed Revenue across 18 years of filings, most recently posting $2.3 billion for Q1 2026.

• In Q1 2026, Revenue rose 10.7% year-over-year to $2.3 billion; the TTM figure through Mar 2026 stood at $24.5 billion (down 20.35% YoY), while the FY2025 annual figure was $62.6 billion, up 646.05% from the prior year.
• Revenue eased to $2.3 billion in Q1 2026, from $17.6 billion in the prior quarter.
• Over the last five years, Revenue for PFE reached as high as $27.7 billion in Q3 2022 and fell as low as $442.0 million in Q3 2024.
• The 5-year median for Revenue is $3.5 billion (2023), against an average of $9.2 billion.
• Annual changes were most pronounced in 2023 — Revenue slumped 92.73% — and 2025, when it surged 419.91%.
• A 5-year view of Revenue shows it stood at $3.3 billion in 2022, then advanced by 5.31% to $3.4 billion in 2023, then sank by 87.13% to $442.0 million in 2024, then jumped by 3872.17% to $17.6 billion in 2025, then sank by 86.68% to $2.3 billion in 2026.
• According to Business Quant data, Revenue over the past three periods registered $2.3 billion, $17.6 billion, and $2.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.